Journey Medical Corporation (DERM)
NASDAQ: DERM · Real-Time Price · USD
7.62
+0.15 (2.01%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Journey Medical Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Journey Medical stock have an average target of 10, with a low estimate of 9.00 and a high estimate of 11. The average target predicts an increase of 31.23% from the current stock price of 7.62.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 6, 2024.
Analyst Ratings
The average analyst rating for Journey Medical stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +18.11% | Sep 6, 2024 |
| Roth MKM | Roth MKM | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +44.36% | Jun 28, 2024 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Initiates $8.5 | Strong Buy | Initiates | $8.5 | +11.55% | Feb 16, 2024 |
| B. Riley Securities | B. Riley Securities | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | -21.26% | Sep 7, 2023 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $3 → $6 | Strong Buy | Maintains | $3 → $6 | -21.26% | Jul 12, 2023 |
Financial Forecast
Revenue This Year
72.88M
from 56.13M
Increased by 29.83%
Revenue Next Year
112.87M
from 72.88M
Increased by 54.88%
EPS This Year
-0.28
from -0.72
EPS Next Year
0.99
from -0.28
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 80.1M | 132.9M | 199.3M |
| Avg | 72.9M | 112.9M | 157.5M |
| Low | 62.8M | 84.3M | 116.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 42.7% | 82.3% | 76.6% |
| Avg | 29.8% | 54.9% | 39.6% |
| Low | 12.0% | 15.6% | 3.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.05 | 2.29 | 3.49 |
| Avg | -0.28 | 0.99 | 1.85 |
| Low | -0.84 | -0.29 | 0.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | 251.1% |
| Avg | - | - | 86.5% |
| Low | - | - | -69.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.